Azeliragon (TTP488 or PF-04494700) is a small-molecule RAGE inhibitor.

It is developed by vTv Therapeutics for various cancers, including triple-negative breast cancer,[1][2] pancreatic cancer.

[3] The chemical reached Phase III trials in slowing cognitive deterioration in early stage Alzheimer's disease patients.

[4][5][6] It was also tested in people with diabetic neuropathy[7] and animal models of graft-vs-host disease.

[8]